PALB2 (Partner And Localizer of BRCA2) encodes a critical DNA repair protein that serves as a central hub in the Fanconi anemia pathway and homologous recombination repair. The protein was identified through its interaction with BRCA2 and functions as a molecular scaffold that coordinates the assembly of DNA repair complexes at sites of damage. PALB2 mutations are associated with Fanconi anemia complementation group N (FA-N), a hereditary bone marrow failure syndrome, as well as dramatically increased risks of breast, ovarian, and pancreatic cancers. Beyond its well-established role in cancer predisposition, emerging evidence suggests that PALB2 and the broader DNA repair machinery have important functions in neuronal survival and may contribute to neurodegenerative processes in Alzheimer's Disease and Parkinson's Disease[1][2].
The importance of PALB2 in maintaining genomic stability stems from its central role in homologous recombination (HR), a high-fidelity DNA double-strand break repair pathway. PALB2 facilitates the loading and stabilization of RAD51 at DNA damage sites, enabling the formation of the nucleoprotein filament necessary for strand invasion and DNA strand exchange. This function is particularly critical in tissues with high cellular turnover and metabolic stress, including the developing brain and aging neurons.
PALB2 was discovered in 2006 through yeast two-hybrid screening as a BRCA2-interacting protein. The acronym "PALB2" reflects its function as a "Partner And Localizer of BRCA2," describing its role in recruiting BRCA2 to DNA damage sites and facilitating its function in homologous recombination. The gene is located on chromosome 16p12.2 and encodes a 1186 amino acid protein that is expressed ubiquitously, with particularly high levels in testis, ovary, and brain.
PALB2 contains several distinct functional domains[3]:
| Domain | Position | Function |
|---|---|---|
| N-terminal WD40 repeat | 1-400 | Protein-protein interactions, chromatin binding |
| Coiled-coil domain | 400-600 | BRCA2 and RAD51 binding |
| Central region | 600-900 | DNA binding, RPA interaction |
| C-terminal region | 900-1186 | Protein complex assembly |
The WD40 repeat region at the N-terminus serves as a scaffold for recruiting multiple DNA repair proteins, while the coiled-coil domain mediates direct interaction with BRCA2. The central region contains DNA-binding activity and interfaces with replication protein A (RPA), and the C-terminal region helps assemble the full repair complex.
PALB2 functions as a molecular bridge in the HR pathway[4][5]:
PALB2 is a core Fanconi anemia pathway component:
PALB2 is essential for homologous recombination-mediated repair:
Key functions:
PALB2 participates in chromatin-based DNA repair[6]:
Beyond DNA repair, PALB2 has transcriptional functions:
PALB2 shows broad expression:
| Tissue | Expression Level |
|---|---|
| Testis | Very high |
| Ovary | High |
| Brain | Moderate-high |
| Breast | Moderate |
| Pancreas | Moderate |
| Bone marrow | Moderate |
In the nervous system[7]:
Expression is particularly high in regions with ongoing neurogenesis and synaptic plasticity, reflecting the importance of DNA repair in these processes.
Neurons are particularly vulnerable to DNA damage due to their non-dividing state and high metabolic activity. Accumulated DNA damage is a hallmark of aging and neurodegenerative diseases[8][9]:
Alzheimer's disease:
Parkinson's disease:
PALB2 and related DNA repair proteins have important neuronal functions[10][11]:
Synaptic function:
Neuronal survival:
DNA repair defects contribute to neurodegeneration through:
PALB2 mutations cause Fanconi anemia complementation group N (FA-N)[12]:
Clinical features:
Inheritance: Autosomal recessive
Mutation types: Biallelic loss-of-function mutations
PALB2 is a high-penetrance cancer susceptibility gene[13][2:1]:
Breast cancer:
Pancreatic cancer:
Ovarian cancer:
While not directly causative, PALB2 dysfunction may contribute to:
For PALB2 mutation carriers and tumors[14][15]:
Surveillance:
Therapeutic strategies:
Emerging approaches:
For neurodegenerative disease prevention:
| Partner | Interaction Type | Function |
|---|---|---|
| BRCA2 | Direct binding | RAD51 loading |
| RAD51 | Direct binding | Filament formation |
| BRCA1 | Indirect | Damage response |
| FANCD2 | Direct binding | FA pathway |
| RPA | Direct binding | DNA binding |
Over 200 pathogenic PALB2 variants identified:
| Mutation Type | Frequency | Examples |
|---|---|---|
| Missense | 35% | p.L24P, p.Y1183C |
| Truncating | 45% | p.R470*, c.509del |
| Splice | 15% | c.2556+1G>A |
| Large del | 5% | Exon deletions |
PALB2 is evolutionarily conserved:
The FA pathway is conserved across eukaryotes, reflecting its fundamental importance in genome maintenance.
PALB2: role in DNA damage response and cancer predisposition. Nature Reviews Cancer. 2014. ↩︎
PALB2 mutations and breast cancer risk. New England Journal of Medicine. 2017. ↩︎ ↩︎
PALB2 protein structure and function. Journal of Molecular Biology. 2018. ↩︎
PALB2 and Fanconi anemia pathway. Molecular Cell. 2019. ↩︎
PALB2 interactions with RAD51 and BRCA1. Nature Structural and Molecular Biology. 2020. ↩︎
PALB2 and chromatin remodeling in DNA repair. Chromosome Research. 2019. ↩︎
PALB2 expression in brain and neurological implications. Journal of Neurochemistry. 2017. ↩︎
DNA damage response in Alzheimer disease. Acta Neuropathologica. 2020. ↩︎
DNA repair in aging and neurodegeneration. Nature Reviews Neuroscience. 2019. ↩︎
BRCA2 and PALB2 in neuronal DNA repair. Cell Death and Differentiation. 2018. ↩︎
DNA damage response proteins in synaptic function. Synapse. 2020. ↩︎
PALB2 mutations in Fanconi anemia. Human Mutation. 2018. ↩︎
PALB2-associated tumor syndrome. Journal of Clinical Oncology. 2018. ↩︎
Therapeutic targeting of PALB2-deficient tumors. Cancer Discovery. 2021. ↩︎
PARP inhibitors in PALB2-related cancers. Clinical Cancer Research. 2021. ↩︎